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Abstract
Background: The prognostic value of body composition in cancer patients has been widely studied during the last
decade. The main finding of these studies is that sarcopenia, or skeletal muscle depletion, assessed by CT imaging
correlates with a reduced overall survival (OS). By contrast, the prognostic value of fat mass remains ill-defined. This
study aims to analyze the influence of body composition including both muscle mass and adipose tissue on OS in
a homogeneous population of advanced colorectal cancer (CRC) patients.
Methods: Among 235 patients with chemorefractory advanced CRC included in the SoMore and RegARd-C trials,
body composition was assessed in 217 patients on baseline CT images. The relationship between body composition
(sarcopenia, muscle density, subcutaneous and visceral fat index and density), body mass index (BMI) and OS were
evaluated.
Results: Patients with a higher BMI had a better OS (≥30 versus < 30, HR: 0.50; 0.33–0.76). Those with low muscle index
and muscle density had an increased mortality (HR: 2.06; 1.45–2.93 and HR: 1.54; 1.09–2.18, respectively). Likewise, low
subcutaneous and visceral fat index were associated with an increased risk of dying (HR: 1.63; 1.23–2.17 and 1.48;
1.09–2.02 respectively), as were a high subcutaneous and visceral adipose tissue density (HR: 1.93; 1.44–2.57 and 2.40;
1.79–3.20 respectively). In multivariate analysis, a high visceral fat density was the main predictor of poor survival.
Conclusions: Our results confirm the protective role of obesity in CRC patients at an advanced stage, as well as
the negative prognostic impact of muscle depletion on survival. More importantly, our data show for the first time that
visceral adipose tissue density is an important prognostic factor in metastatic CRC.
Trial registration: NCT01290926, 07/02/2011 and NCT01929616, 28/08/2013.
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Background
Malnutrition has been known for more than 30 years to
be associated with reduced overall survival (OS) of cancer
patients [1] and is present in one third of colorectal cancer
(CRC) cases [2]. On the other hand, the prevalence of
overweight and obesity has dramatically increased during
the last 3 decades [3] and obesity is now widely recognized
as a risk factor for several cancer types, including CRC [4].
As a result, the clinical picture of malnutrition in cancer
patients has changed and recent diagnostic criteria for
cancer cachexia emphasize on loss of muscle mass, known
as sarcopenia, along with weight loss and low body mass
index (BMI) [5]. Accordingly, several techniques have
been developed in order to evaluate body composition.
Among these, dual X-ray absorptiometry (DEXA) is con-
sidered the gold standard but is rarely used in clinical
practice where bioelectrical impedance analysis and com-
puted tomography (CT)-based regional body composition
analysis are more readily available [6].
CT-based regional analysis of muscle and adipose tissue
at the level of the third lumbar vertebra strongly correlates
with whole-body fat and muscle mass [7], making it an at-
tractive way to evaluate body composition in cancer pa-
tients, since anyhow CTs are routinely performed during
their follow up. Moreover, the mean muscle attenuation
expressed in Hounsfield units (HU) also gives a qualitative
information, a lower attenuation being associated with a
higher muscle lipid content [8]. Skeletal muscle depletion
as assessed by CT imaging has been associated with a re-
duced OS in multiple studies [9]. By contrast, little is
known regarding the prognostic impact of adipose tissue
area and density in cancer patients, even though these pa-
rameters are easily measured on the CT images used for
the evaluation of skeletal muscle [7].
The aim of this study was to assess the association of
BMI, skeletal muscle and adipose tissue mass and dens-




All patients included in the SoMore (NCT01290926, 07/
02/2011) [10] and the RegARd-C (NCT01929616, 28/08/
2013) [11] clinical trials were evaluated in the present
study. Both studies were single arm, prospective, open
label, non-randomized, multicenter clinical trials, asses-
sing the prognostic significance of early metabolic re-
sponse to treatment in chemorefractory metastatic CRC
patients. The SoMore study enrolled 97 patients between
February and October 2011 to receive capecitabine in
combination with sorafenib. For RegARd-C, 138 patients
were enrolled between August 2013 and August 2014
and received regorafenib as a monotherapy. Eligible pa-
tients for both trials had progressive disease after
treatment with 5FU, oxaliplatin, irinotecan as well as
bevacizumab and anti-EGFR antibodies as appropriate.
Patients with an ECOG performance status > 1, i.e. pa-
tients unable to carry out light or sedentary work, were
not eligible. All patients received a baseline 18F-fluoro-
deoxyglucose (FDG)-positron emission tomography
(PET) combined with CT. After exclusion of patients
without follow up data allowing determination of OS or
whose CT was not appropriate for body composition
evaluation, 88 patients (91%) of the SoMore study and
129 patients (93%) of the RegARd-C study were included
in the final analysis. Overall survival in months was de-
fined as the time from inclusion to the date of death
from any cause. Given the similar inclusion criteria and
the fact that regorafenib and sorafenib are closely related
multikinase inhibitors with limited benefit in our study
population [10, 12], the 217 eligible patients were treated
as a single patient population.
Body mass index and CT-based body composition analysis
BMI (kg/m2) was calculated as weight in kilograms di-
vided by the square of height in meters. BMI was then cat-
egorized according to the World Health Organization
modified by Martin et al. (underweight < 20.0, normal
weight 20.0–24.9, overweight 25.0–29.9, obesity ≥30.0)
[13]. Evaluation of body composition was performed using
the PLANET Onco® software (DOSIsoft, Cachan, France)
by two independent investigators. The cross-sectional area
(cm2) of skeletal muscle (psoas, paraspinal and abdominal
wall muscles), subcutaneous adipose tissue and visceral
adipose tissue was delineated on two adjacent CT slices at
the level of the third lumbar vertebra. Skeletal muscle,
subcutaneous adipose tissue and visceral adipose tissue
were defined by ranges of − 29 to 150, − 190 to − 30 and
− 150 to − 50 HU, respectively [7]. Muscle and fat areas
(cm2) were normalized for the square of height (m2) as in-
dexes (cm2/m2). Figure 1 shows an example of the result-
ing images in a sarcopenic and a non-sarcopenic patient.
Additionally, the mean attenuation (HU) for each area
was recorded. Interobserver agreement was excellent for
all body composition parameters with r2 ranging from
0.95 to 1.0.
Sarcopenia was defined as a skeletal muscle index < 41
in women, < 43 in men with a BMI < 25, and < 53 in
men with a BMI ≥ 25. These cut offs have been validated
in a large population of cancer patients [13]. Since there
is no validated definition of low fat mass in cancer pa-
tients based on CT-imaging, an optimal cutoff was de-
termined in our study population.
Statistical analysis
The Mann-Whitney-Wilcoxon test and the chi-square
or Fisher exact test were used to assess differences in
continuous and categorical variables, respectively. The
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association between two continuous variables was
assessed with Spearman correlation. To assess the het-
erogeneity between SoMore or RegARd-C, we used the
chi-square test.
The primary outcome was OS. To assess whether
gender-specific cutoffs or BMI-specific cutoffs for each
of the six body composition variables were needed, we
fitted a multivariate Cox’s proportional hazards model
containing, that variable, gender, BMI (≤25 vs > 25) and
the two two-way interactions (variable*gender, variable*-
BMI25) and the three-way interaction (variable*gen-
der*BMI25). We performed backward variable selection.
If e.g. the interaction variable*gender would be retained,
this would indicate that the effect of the variable on OS
depends on the gender, and thus stratifying by gender
would be of interest when calculating the optimal cutoff.
The optimal cutoff in each of the six body composition
parameters was determined by the SASmacro %findcut
[14]. The outer 20% of the continuous variable distribu-
tion were excluded in this analysis to avoid having small
numbers in one of the groups following dichotomiza-
tion, to prevent substantial losses in statistical power.
For the univariate analysis, Kaplan-Meier curves were
used to compare OS of patients below or above the opti-
mal cutoff determined for each body composition par-
ameter. The hazard ratio (HR) and 95% confidence
interval (CI) were calculated using Cox’s proportional
hazards model, and logrank tests were used to compare
survival curves.
For the multivariate analysis, a stepwise variable selec-
tion was performed, considering the study subset
(SoMore vs RegARd-c), age, BMI (4 categories), gender,
performance status, time interval between diagnosis and
inclusion in the respective study (SoMore or RegARd-c),
low skeletal muscle index, low muscle density, low
subcutaneous adipose tissue index, high subcutaneous
adipose tissue density, low visceral adipose tissue index
and high visceral adipose tissue density. Results were
considered statistically significant at the bilateral p < 0.05
level. SAS version 9.4 was used for all statistical analyses.
This study has been approved by the ethics committee
of Institut Jules Bordet and has been performed in ac-
cordance with the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments.
Results
Patient characteristics
Among the 217 subjects included in the present study,
94 (43%) were women and 123 (57%) were men. Median
BMI was 24.9 (14.1–41.0) with 49% of these heavily
pre-treated patients being overweight or obese. Sarcope-
nia was present in 150 (69%) of the study population. Al-
though sarcopenia was less prevalent in obese patients
as compared to non-obese, it was still observed in 48%
of this subgroup. Table 1 shows the baseline characteris-
tics of the patients in both study subsets.
At the time of analysis, 197 (90%) of the patients had
died. Median OS (mOS) was 8.2 months (6.8–10.4) in the
SoMore study and 7.1 months (3.4 to 13.3) in the
RegARd-C study. To make sure that data from these 2 tri-
als could be pooled, a test for heterogeneity comparing
SoMore and RegARd-C patients was performed for each
body composition variable dichotomized considering the
gender-specific median in each dataset (Table 2). This test
found no evidence that the effect of body composition on
OS could be dependent of the considered dataset, allow-
ing us to pool the data for further evaluation.
A wide variation in body composition was found be-
tween men and women. Women had a lower BMI
(mean ± SD, women: 24.5 ± 5.5 vs men: 26.3 ± 4.1, p < 0.001)
and skeletal muscle index (women: 36.2 ± 5.8 vs men:
46.6 ± 9.2, p < 0.001). Men had a lower subcutaneous
fat index (women: 74.8 ± 45.2 vs men: 56.2 ± 29.9, p = 0.002)
but a higher visceral fat index (women: 29.8 ± 26.2 vs
men: 55.9 ± 33.7, p < 0.001) and lower visceral adipose tis-
sue density (women: − 87.4 ± 10.1 vs men: − 90.8 ± 8.9,
Fig. 1 CT images of the third lumbar vertebra region in a sarcopenic (a) and a non-sarcopenic (b) patient
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p = 0.006). BMI was significantly correlated with skeletal
muscle index (r = 0.49; p < 0.001), subcutaneous fat index
(r = 0.73; p < 0.001), and visceral fat index (r = 0.75;
p < 0.001) but was inversely correlated with muscle
density (r = − 0.36; p < 0.001), subcutaneous fat density
(r = − 0.60; p < 0.001), and visceral fat density (r = − 0.62;
p < 0.001).
Survival and optimal stratification
In univariate analysis, obesity was associated with an in-
crease in OS (BMI ≥30 vs < 30, HR for mortality 0.50
(0.33–0.76)). Neither the presence of sarcopenia nor a
low muscle density according to a validated cutoff [13]
were associated with survival (HR 1.28 (0.93–1.75) and
1.25 (0.89–1.77), respectively).
However, a skeletal muscle index below the gender-spe-
cific median was associated with increased mortality in
both subsets, as shown in Table 2, suggesting that muscle
loss had a prognostic impact indeed. Since published cut-
offs for skeletal muscle index and muscle density failed to
predict mortality in our cohort and no validated cutoffs
for subcutaneous fat index, subcutaneous fat density, vis-
ceral fat index or visceral fat density could be found in the
existing literature, the optimal cutoff associated with lower
survival was assessed for each body composition variable.
Gender and BMI were taken into account in the model
but no statistically significant interaction between these
variables and body composition were found, thus alleviat-
ing the need to stratify the population by gender or BMI.
The optimal cutoff for association with OS for each body
composition variable is shown in Table 3.
Patients with a skeletal muscle index and muscle dens-
ity below these thresholds had an increased mortality,
with HR of 2.06 (1.45–2.93) and 1.54 (1.09–2.18), re-
spectively. Low subcutaneous and visceral fat index were
also associated with an increased risk of dying, with








Mean ± std 61 ± 10 65 ± 11 63 ± 11
Median (min-max) 63 (28 to 83) 67 (32 to 85) 65 (28 to 85)
Gender
Female 38 43% 56 43% 94 43%
Male 50 57% 73 57% 123 57%
BMI
Mean ± std 25.3 ± 4.7 25.6 ± 5.0 25.5 ± 4.9
Median (min-max) 25.4 (16.5 to 35.6) 24.4 (14.1 to 41.0) 24.9 (14.1 to 41.0)
ECOG PS
0 49 56% 63 49% 112 52%
1 39 44% 66 51% 105 48%
Years between diagnosis and inclusion in the trial
Mean ± std 3.3 ± 2.6 3.7 ± 2.6 3.5 ± 2.6
Median (min-max) 2.3 (0.2 to 14.9) 3.0 (0.1 to 13.0) 2.6 (0.1 to 14.9)
Table 2 Test for heterogeneity comparing SoMore and RegARd-C
SoMore RegARd-c P-value
Test heterogeneityHazard ratio (95% CI) Hazard ratio (95% CI)
Muscle index (low vs high) 1.55 (1.00 to 2.38) 1.86 (1.28 to 2.72) 0.53
Muscle density (low vs high) 0.74 (0.48 to 1.14) 1.12 (0.78 to 1.63) 0.15
Subcutaneaous fat index (low vs high) 1.08 (0.70 to 1.66) 1.81 (1.24 to 2.64) 0.08
Subcutaneous fat density (low vs high) 0.64 (0.41 to 0.98) 0.53 (0.37 to 0.77) 0.52
Visceral fat index (low vs high) 1.21 (0.79 to 1.86) 1.59 (1.09 to 2.31) 0.35
Visceral fat density (low vs high) 0.60 (0.39 to 0.92) 0.42 (0.28 to 0.61) 0.23
Hazard ratio for OS were calculated for muscle index, muscle density, subcutaneous fat index, subcutaneous fat density, visceral fat index and visceral fat density
comparing patients above and below the gender-specific median in each dataset. A test for heterogeneity comparing the two datasets for each body composition
parameter was then performed and did not reach statistical significance
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hazard ratios of 1.63 (1.23–2.17) and 1.48 (1.09–2.02),
respectively. Finally, a high subcutaneous and visceral fat
density were also correlated with mortality, with a HR of
1.93 (1.44–2.57) and 2.40 (1.79–3.20), respectively. The
corresponding survival curves are shown in Fig. 2 A-F.
Multivariate analysis
A multivariate analysis was then performed, taking into
account the population subset (SoMore vs RegARd-C
study participants), age, BMI (obese, overweight, normal,
underweight), gender, performance status, time interval
between diagnosis and inclusion in the study (SoMore
or RegARd-C), low skeletal muscle index, low muscle
density, low subcutaneous fat index, high subcutaneous
fat density, low visceral fat index, high visceral fat dens-
ity. Results are shown in Table 4 and demonstrate that
BMI (obese or not), time interval from diagnosis till in-
clusion, low skeletal muscle index, low muscle density
and high visceral fat density are independently and sig-
nificantly associated with a reduced OS. Moreover, the
main factor predicting survival seems to be high visceral
fat density.
Discussion
In this study, we measured skeletal muscle mass as well
as subcutaneous and visceral fat mass in a population
that is highly homogeneous from an oncologic perspec-
tive. Indeed, all patients had been heavily pretreated for
a metastatic CRC and received similar although not
identical treatments in both study cohorts. More than
two thirds of these selected patients were sarcopenic,
which is in line with the results of another study asses-
sing the presence of sarcopenia in metastatic CRC pa-
tients [15] but much higher than the 39% of sarcopenic
patients found in a cohort of early stage CRC patients
surgically treated with curative intent [16]. Our results
also dramatically differ from the 31.2% prevalence of
malnutrition found in CRC patients using weight loss
and BMI but not body composition [2], highlighting the
need to integrate body composition parameters in the
nutritional evaluation of these patients. However, sarco-
penia as defined by validated cutoffs was not correlated
with OS. This is unlikely to be due to a lack of statistical
power considering our sample size and number of
events. Alternatively, one may hypothesize that the use
of different software could lead to slightly different re-
sults. This is also unlikely because a recent study found
an excellent agreement for the diagnosis of sarcopenia
based on several softwares [17]. Since the cutoffs for sar-
copenia have been derived from a large population com-
prising patients with different cancer types at various
stages of their disease [13], it may be hypothesized that
these cutoffs do not fit our highly homogeneous popula-
tion of very advanced colorectal cancer patients.
Conversely, our cutoffs for sarcopenia may thus not be
generalized to other patient populations. Nonetheless,
our results clearly show that a reduced muscle mass cor-
relates with a reduced survival in CRC patients which is
in line with results found in mixed cancer patients popu-
lation [9, 13].
Another important finding of our study is the associ-
ation of obesity with an increased OS, which is a typical
example of the obesity paradox. Indeed, obesity is a
known risk factor for colon cancer incidence and mor-
tality in healthy subjects [4, 18]. The relation between
survival and the presence of obesity after a diagnosis of
CRC is less clear. In stage II and III CRC, obese patients
have a reduced OS [19]. By contrast, obesity was not as-
sociated with a reduced OS in patients with metastatic
CRC undergoing chemotherapy [20]. The obesity para-
dox is often considered to reflect statistical bias and re-
verse causality rather than an established biological
phenomenon [21]. The post-hoc nature of our analysis
does not allow us to exclude such bias. However, our
data were prospectively collected and obesity was found
to predict OS in a multivariate analysis taking several
other body composition-related factors into account.
Moreover, several prognostic models in mixed cancer
patient populations show a protective role of overweight
and/or obesity [13, 22]. Another potential explanation to
the obesity paradox in cancer patients is the failure of
most of the studies exploring the relation of BMI and
survival to take the body composition into account. The








Skeletal muscle index 47.5 54 (25%) 163 (75%)
Muscle density 22.5 175 (81%) 42 (19%)
Subcutaneous fat index 50 129 (59%) 88 (41%)
Subcutaneous fat density -100 110 (51%) 107 (49%)
Visceral fat index 60 64 (29%) 153 (71%)
Visceral fat density −90 102 (47%) 115 (53%)
Skeletal muscle index, subcutaneous fat index, visceral fat index are expressed
in cm2/m2; muscle density, subcutaneous fat density, visceral fat density are
expressed in HU




BMI obese 0.60 (0.38 to 0.95) 0.03
Years diagnosis till inclusion Per one-year 0.89 (0.84 to 0.95) < 0.001
Skeletal muscle index Low, < 47.5 1.49 (1.04 to 2.15) 0.03
Muscle density Low, < 22.5 1.80 (1.24 to 2.61) 0.002
Visceral fat density High, ≥90 1.87 (1.38 to 2.54) < 0.001
Obese: BMI ≥ 30 kg/m2; skeletal muscle index expressed in cm2/m2; muscle
and visceral fat density expressed in HU
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general finding when muscle mass is considered is that
obesity in not associated with a better OS in the pres-
ence of low muscle mass. The low prevalence of sarco-
penia in obese patients could thus account for the better
prognosis associated with high BMI [23]. Indeed, several
studies have found a low prevalence of sarcopenia in
obese patients. One study evaluating 995 patients at hos-
pital admission found sarcopenia in only 1% of obese pa-
tients [24]. In another study evaluating obese patients
with colorectal or lung cancer, the prevalence of sarco-
penia was only 15% [25]. Similarly, another study in
obese CRC patients undergoing surgery found sarcope-
nia in 16% of the cases [16]. Most of the patients in
these two studies had no metastases. By contrast, sarco-
penia was present in 48% of obese patients in our co-
hort, and obesity was still associated with a better
survival in a multivariate model taking muscle mass into
account, making this last explanation unlikely in our
study. Therefore, we think that our observation regard-
ing obesity and survival is not a statistical artefact. One
explanation could be a different role of obesity depend-
ing on the stage of the disease where the adverse meta-
bolic and inflammatory status takes precedence in early
disease stages whereas the larger amount of energy
stored in adipose tissue becomes increasingly important
in advanced disease.
While the prognostic impact of low muscle mass has
been shown in numerous studies, the role of adipose tis-
sue mass and density has received much less interest,
and research on this topic has yielded conflicting results.
For instance, a high visceral fat area was associated with
a shorter disease free survival in breast cancer patients
Fig. 2 Survival curves based on skeletal muscle index (a), muscle density (b), subcutaneous fat index (c), visceral fat index (d), subcutaneous fat
density (e) and visceral fat density (f). Patients with skeletal muscle index and muscle density below the thresholds had an increased mortality. Low
subcutaneous and visceral fat index were also associated with an increased risk of dying. Finally, a high subcutaneous and visceral fat density also
correlated with mortality
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treated with neoadjuvant chemotherapy [26]. By con-
trast, patients with a high visceral fat area and high vis-
ceral fat density had a longer time to biochemical
recurrence after curative treatment of prostate cancer,
although their predictive value was lost in a multivariate
model including all risk factors grouped together accord-
ing to the CAPRA-S score [27]. Similarly, both low and
high visceral adipose tissue index have been associated
with a reduced OS in patients receiving immunochem-
otherapy for diffuse large B-cell lymphoma [28, 29]. In
CRC, a high visceral fat area has been associated with a
shorter OS in patients treated with bevacizumab but not
in those treated with chemotherapy alone [30]. In our
study, both a low visceral and subcutaneous fat index
were associated with a reduced OS only in univariate
analysis but failed to reach statistical significance in
multivariate analysis. However, our results point to an
important prognostic role of the adipose tissue. Indeed,
high visceral fat density was strongly associated with a
reduced survival. To the best of our knowledge, no
previous study has assessed the prognostic role of fat
density in metastatic cancer patients. However, higher
adipose tissue density was associated with mortality in
two large cohorts of healthy older adults [31]. As for
muscle density, adipose tissue density might be a quali-
tative marker whereas adipose tissue index reflects the
quantity of adipose tissue. Theoretically, a higher fat
density could reflect a depletion of fat storage associated
with poor nutritional status. Indeed, in one study in can-
cer patients and rats, the radiologic density of brown
adipose tissue increased with activation. In rats, this
higher brown adipose tissue density was associated his-
tologically with a lower lipid content [32]. Higher adi-
pose tissue density has also been associated with smaller
adipocytes in non-human primates [31]. Alternatively,
the subcutaneous adipose tissue of cachectic patients
with gastro-intestinal cancer is characterized by fibrosis
and inflammatory cell infiltration [33]. Although no
radiological correlations were made in this study, fibrosis
and inflammation should also lead to increased adipose
tissue density. Another explanation for a higher adipose
tissue density could be a browning of the adipose tissue,
a phenomenon involved in cancer cachexia [34]. Inter-
estingly, a cutoff of − 88 HU has been proposed to differ-
entiate brown from white adipose tissue [35], which is
close to our optimal cutoff for association with OS of −
90 HU. Whether the prognostic impact of adipose tissue
density in our study is mediated by malnutrition, brown-
ing of the adipose tissue, the role of inflammation and/
or altered adipokines remains to be investigated.
Conclusion
Our results confirm the protective role of obesity in can-
cer patients at an advanced stage, as well as the negative
prognostic impact of low muscle index and muscle dens-
ity. Finally, and more importantly, this work shows for
the first time in metastatic cancer patients that visceral
adipose tissue density is an important prognostic factor
even when well-known oncologic prognostic variables
such as performance status and length of disease are
taken into account. Further research is needed to con-
firm these findings regarding adipose tissue, which may
help to better define the prognosis of advanced colorec-
tal cancer patients in the future.
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